Perspectives on Loading Dose and Treatment Extension With New Therapies
Experts discuss the approach to loading doses in the context nAMD and DME. Kaiser, MD explains that loading doses may not be necessary based on studies like the CAT study, while he highlights the importance of individualized treatment plans tailored to the specific needs of each patient and the nuances of different retinal diseases.
EP: 1.Navigating Step Therapy in nAMD and DME
EP: 2.Role of Biosimilars in nAMD and DME Step Therapy
EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg
EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice
EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME
EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies
EP: 7.Using Steroids in DME Treatment
EP: 8.Patient Selection for New nAMD and DME Therapies
EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg
EP: 10.Safety Considerations for New Therapies
EP: 11.Promoting Treatment Adherence in nAMD and DME
Summary
The retinal specialists discuss the use of loading doses in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). They share insights from studies indicating that a loading dose may not significantly impact visual acuity outcomes, referencing the CAT study as an example. The physicians emphasize individualized treatment approaches, such as treating to dryness and using a treat-and-extend regimen based on patient response rather than fixed dosing intervals. They discuss extending treatment intervals based on patient response and the specific characteristics of each disease, highlighting the importance of flexibility and considering patient preferences in treatment decisions. Additionally, they note the complexity of managing these conditions and the need for careful consideration beyond simply administering injections.
This summary was AI-generated and edited for clarity.
